



ORIX Life Launches New Specified Disease Insurance Product “With”, An Industry-First Fixed-Term No Cash-Surrender Type Insurance

TOKYO, Japan – April 22, 2016 – ORIX Life Insurance Corporation (“ORIX Life”), a subsidiary of ORIX Corporation today announced that it will launch “With”, a specified disease insurance product on May 2, 2016¹. This is the industry’s first fixed-term no cash-surrender specified disease insurance product².

ORIX Life has developed insurance products with the mission of meeting our customer needs through products such as “New CURE” medical insurance, “New CURE Lady” medical insurance, “RISE” whole life insurance, and “Keep” income protection insurance, as well as with our relaxed underwriting condition insurance options “New CURE Support” medical insurance, and “New RISE Support” whole life insurance, based on our product concept of being “simple and easily understood” and “reasonable insurance at an affordable price.”

According to the survey³ conducted by ORIX Life, more than half of the respondents said that they would feel concern about the financial burdens if they suffer cancer, myocardial infarction⁴ or cerebral stroke. In order to eliminate such concerns, “With” specified disease insurance was newly developed as insurance which allows the insured to maintain the same quality of life even during the leave of absence from work for long-term treatment.

Furthermore, we’ve tried to make this insurance easy to understand, and have added options such as additional coverage for surgery to treat acute myocardial infarction or cerebral stroke.

In order to meet the diverse needs of our customers, we are offering an insurance product lineup that enables customers to select insurances that suit their lifestyles, such as the industry’s first fixed-term with no cash-surrender for those who want to ensure protection for a certain period of time at an affordable price, and whole life coverage with a low cash-surrender value for those who seek whole life protection with a savings component.

ORIX Life will continue to provide products that anticipate the needs of the market, and will continue to be the preferred insurance company of customers.

Contact Information:

ORIX Corporation
Corporate Planning Department
Tel: +81-3-3435-3121

About ORIX:

ORIX Corporation (TSE: 8591; NYSE: IX) is a financial services group which provides innovative products and services to its customers by constantly pursuing new businesses. Established in 1964, from its start in the leasing business, ORIX has advanced into neighboring fields

¹ In conjunction with this release, sales of current specified disease insurance will cease on May 1, 2016.

² This is the industry’s first specified disease fixed-term no cash-surrender insurance with death benefit to cover cancer, acute yocardial infarction, and cerebral stroke (according to research by ORIX Life)

³ Online survey of 1,000 conducted from December 10, 2013 to December 11, 2013.

⁴ Commonly known as heart attack

and at present has expanded into the lending, investment, life insurance, banking, asset management, automobile-related, real estate and environment and energy-related businesses. Since its first overseas expansion into Hong Kong in 1971, ORIX has spread its business globally by establishing locations in a total of 36 countries and regions across the world. Moving forward, ORIX aims to contribute to society while continuing to capture new business opportunities. For more details, please visit our website: <http://www.orix.co.jp/grp/en/>

Caution Concerning Forward Looking Statements:

These documents may contain forward-looking statements about expected future events and financial results that involve risks and uncertainties. Such statements are based on our current expectations and are subject to uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that could cause such a difference include, but are not limited to, those described under “Risk Factors” in the Company’s annual report on Form 20-F filed with the United States Securities and Exchange Commission and under “4. Risk Factors” of the “Summary of Consolidated Financial Results” of the “Consolidated Financial Results April 1, 2014 – March 31, 2015.”